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Abstract
Purpose To prospectively evaluate the association of
vitamin/mineral supplementation with cancer, cardiovas-
cular, and all-cause mortality.
Methods In the Heidelberg cohort of the European Pro-
spective Investigation into Cancer and Nutrition (EPIC-
Heidelberg), which was recruited in 1994–1998, 23,943
participants without pre-existing cancer and myocardial
infarction/stroke at baseline were included in the analyses.
Vitamin/mineral supplementation was assessed at baseline
and during follow-up. Cox regression models were used to
estimate hazard ratios (HRs) and 95% confidence intervals
(CIs).
Results After an average follow-up time of 11 years,
1,101 deaths were documented (cancer deaths = 513 and
cardiovascular deaths = 264). After adjustment for poten-
tial confounders, neither any vitamin/mineral supplemen-
tation nor multivitamin supplementation at baseline was
statistically significantly associated with cancer, cardio-
vascular, or all-cause mortality. However, baseline users of
antioxidant vitamin supplements had a significantly
reduced risk of cancer mortality (HR: 0.52; 95% CI: 0.28,
0.97) and all-cause mortality (HR: 0.58; 95% CI: 0.38,
0.88). In comparison with never users, baseline non-users
who started taking vitamin/mineral supplements during
follow-up had significantly increased risks of cancer mor-
tality (HR: 1.74; 95% CI: 1.09, 2.77) and all-cause mor-
tality (HR: 1.58; 95% CI: 1.17, 2.14).
Conclusions Based on limited numbers of users and
cases, this cohort study suggests that supplementation of
antioxidant vitamins might possibly reduce cancer and all-
cause mortality. The significantly increased risks of cancer
and all-cause mortality among baseline non-users who
started taking supplements during follow-up may suggest a
‘‘sick-user effect,’’ which researchers should be cautious of
in future observational studies.
Keywords Supplements  Cancer  Cardiovascular
disease  Mortality  Cohort study
Introduction
Taking vitamin/mineral supplements is common in affluent
countries. In Germany, a study in 1998 reported that 18%
of men and 25% of women were regular users in a sample
of population aged 18–79 years [1]. Nowadays the preva-
lence should be higher, particularly in elderly populations.
Some epidemiological studies have investigated the effects
of vitamin/mineral supplementation on cancer, cardiovas-
cular disease (CVD), and all-cause mortality. However, the
inconsistent findings obtained from these studies do not
allow for drawing a clear conclusion. As reported by a US
prospective cohort study, long-term daily use of multivi-
tamin supplements was significantly inversely associated
with CVD mortality [2], while in another cohort, this
inverse association was not observed [3]. In the Cancer
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Prevention Study II (CPS-II), use of multivitamin plus
vitamin A, C, and E was significantly inversely associated
with all-cause mortality [4]. Nevertheless, multivitamin
supplements alone did not show this beneficial effect in
other studies [2, 5]. Surprisingly, two studies have
observed a significantly increased risk of cancer mortality
among male current smokers who took either multivitamin
supplements or non-specific dietary supplements [4, 6],
suggesting that vitamin/mineral supplements might be
harmful for specific population groups.
In the present study, we evaluated the associations of
vitamin/mineral supplementation with cancer, CVD, and
all-cause mortality in the Heidelberg cohort of the Euro-
pean Prospective Investigation into Cancer and Nutrition
(EPIC-Heidelberg).
Subjects and methods
Study population
The EPIC-Heidelberg cohort was recruited in 1994–1998.
Detailed recruitment procedures have been described
elsewhere [7]. This cohort eventually recruited 25,540
local residents, including 11,928 men (age range:
40–64 years) and 13,612 women (age range: 35–64 years).
The Ethics Committee of the Heidelberg University Med-
ical School approved the study protocol. Written informed
consents were obtained from all participants. In the present
study, we excluded participants who had a diagnosis of
cancer (n = 953) or myocardial infarction (MI)/stroke
(n = 678) at recruitment stage, leaving 23,943 participants
(11,083 men and 12,860 women) for analysis.
Data collection
Assessment of vitamin/mineral supplementation
and other exposures
In the EPIC-Heidelberg cohort, vitamin/mineral supple-
mentation was assessed at different time points. In a
baseline face-to-face interview, regular use of vitamin/
mineral supplements was assessed by asking participants
the following question: ‘‘Did you regularly take any med-
ications or vitamin/mineral supplements in the last
4 weeks?,’’ where regular use was defined as daily use that
lasted for C1 week or non-daily use of C5 doses at regular
intervals. For participants who answered ‘‘yes,’’ brand
names of the supplements were further asked for. In a
baseline self-administered food frequency questionnaire
(FFQ), participants were also asked whether they had taken
vitamin/mineral supplements for C4 weeks in the last
12 months. These two baseline assessments produced a
weighted Kappa coefficient of 0.87. Regular vitamin/min-
eral supplementation was reassessed in the 2nd
(2001–2003) and the 3rd (2004–2006) self-administered
follow-up questionnaire survey using the same definition of
regular use as used in the baseline face-to-face interview.
The present study analyzed the vitamin/mineral supple-
mentation data from the baseline face-to-face interview.
Supplementation data of the 2nd and the 3rd follow-up
survey were also used to deal with the question of stability
of supplementation. There was no data missing in the
baseline face-to-face interview as all participants answered
the supplement use question. In follow-up questionnaires,
tick boxes that were left unmarked were considered as non-
use. Dose data were not collected at all these occasions.
Intakes of 148 food and beverage items in the last
12 months before recruitment were measured using the
baseline FFQ, which had been validated by twelve 24-h
dietary recalls [8, 9]. Baseline demographic, lifestyle, and
other health-related characteristics were measured in a
baseline lifestyle questionnaire survey and a baseline
physical examination.
Ascertainment of end points
Fatal status was identified by means of regular follow-up
surveys. The underlying cause of death was verified by
reviewing official death certificate and was coded using the
International Classification of Diseases 10th version (ICD-
10). In the present study, the end points of interest included
cancer deaths (B21 and C00-C97), CVD deaths (I00-I99),
and all-cause deaths.
Statistical analysis
Age- and sex-adjusted baseline characteristics of non-users
and users of any vitamin/mineral supplements were com-
pared using analysis of covariance and logistic regression.
We further classified any vitamin/mineral supplements into
multivitamins, antioxidant vitamins (including vitamin A,
C, E, and their combinations), and others. Hazard ratios
(HRs) and 95% confidence intervals (CIs) were estimated
using Cox proportional hazards models, in which age at
recruitment and age at death (or age at the last contact in
case of censoring) were used as separate time scales. In
order to avoid violation of the proportional hazard
assumption, age at recruitment (1-year category) was used
as a strata variable. The following possible confounders,
which were selected from baseline characteristics using the
change-in-estimate method with the entry criterion being a
5% or greater alteration in the exposure-disease effect,
were adjusted for: sex, educational level (no/primary,
technical/secondary, and university), body mass index
(BMI, kg/m2), waist-to-hip ratio, smoking category (never
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smokers; former smokers, quit C10 years, quit \10 years;
and current smokers, B10, 11–20, [20 cigarettes/day),
intake of meat/meat products (g/day), and baseline regular
use of non-steroidal anti-inflammatory drugs (NSAIDs,
yes/no). As important risk factors for cancer and CVD,
physical activity (inactive, moderately inactive, moderately
active, and active [10]) and total energy intake (kcal/day)
were also adjusted for, although they slightly missed the
entry criterion. For any vitamin/mineral supplementation,
we also performed a 2-year lag analysis by excluding
deaths that occurred in the first 2 years of follow-up and a
stratified analysis by sex and smoking status (never, for-
mer, and current smoking).
To deal with the question of stability of supplement use
during follow-up, we performed a sub-analysis of 19,873
participants who provided supplementation information at
all three occasions, i.e. the baseline face-to-face interview,
the 2nd and the 3rd follow-up survey. In this sub-analysis,
participants were categorized into five groups: (1) never
users, defined as participants who did not take vitamin/
mineral supplements at all three occasions; (2) new users,
defined as baseline non-users who started taking vitamin/
mineral supplements during follow-up; (3) former users,
defined as baseline users who stopped taking vitamin/
mineral supplements during follow-up; (4) consistent users,
defined as participants who took vitamin/mineral supple-
ments at all three occasions; and (5) casual users, defined
as participants who did not belong to any of the above
groups. The sub-analysis counted the survival time from
the date of the 3rd follow-up survey and used never users
as the reference.
A two-sided p \ 0.05 was considered as statistically
significant. All analyses were performed with SAS soft-
ware (version 9.2; SAS Institute, Cary, NC, USA).
Results
According to the face-to-face interview, 34.4% of the
EPIC-Heidelberg cohort participants were regular users of
any vitamin/mineral supplements. 56.3% of users pro-
vided the brand names of the supplements. Among them,
multivitamins, with or without minerals, were the most
commonly used supplements (28.6%), followed by anti-
oxidant vitamins (18.1%). The prevalence of any vitamin/
mineral supplementation kept increasing during follow-up
(39.0% in the 2nd and 44.6% in the 3rd follow-up
survey).
As shown in Table 1, users of any vitamin/mineral
supplements were more likely to have some favorable
health-related characteristic, such as having a university
degree, being physically active, having a lower BMI and a
generally healthier diet, which was indicated by higher
intakes of fruits/vegetables and milk/milk products but a
lower intake of meat/meat products. On the other hand,
users were older than non-users and more likely. To be
women and to have a longer smoking duration. Users of
any vitamin/mineral supplements were also more likely to
Table 1 Age- and sex-adjusted
baseline characteristics of
baseline non-users and users of
any vitamin/mineral
supplements, the EPIC-
Heidelberg cohort, 1994–1998
Values are adjusted means or
percentages obtained by using
analysis of covariance or
logistic regression
Participants with a diagnosis of
cancer or MI/stroke at baseline
were excluded
BMI body mass index, EPIC
European Prospective
Investigation into Cancer and
Nutrition, MI myocardial
infarction, NSAIDs non-
steroidal anti-inflammatory
drugs
Non-users (n = 15,813) Users (n = 8,130) p value
Age at recruitment (years) 50.0 51.7 \0.001
Men (%) 51.4 36.3 \0.001
University degree (%) 29.1 32.7 \0.001
Physically active (%) 24.4 26.3 0.001
BMI (kg/m2) 26.2 25.9 \0.001
Waist-to-hip ratio 0.87 0.86 0.43
Current smokers (%) 24.1 22.3 0.002
Smoking duration (years) 12.0 12.4 0.03
Lifetime alcohol consumption (g/day) 17.1 17.1 0.72
Intake of fruits/vegetables (g/day) 239.0 249.9 \0.001
Intake of milk/milk products (g/day) 236.7 269.4 \0.001
Intake of cereal foods (g/day) 190.4 190.0 0.74
Intake of meat/meat products (g/day) 100.8 92.3 \0.001
Total energy intake (kcal/day) 1,980 1,963 0.09
Hypertension at recruitment (%) 28.7 29.0 0.67
Hyperlipidemia at recruitment (%) 34.6 37.6 \0.001
Type 2 diabetes at recruitment (%) 3.9 3.4 0.04
Antihypertensive drug users (%) 13.1 16.2 \0.001
Lipid-lowering drug users (%) 3.4 4.4 \0.001
NSAIDs users (%) 4.9 8.6 \0.001
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take antihypertensive drugs, lipid-lowering drugs, and
NSAIDs.
After an average follow-up time of 11 years, 1,101
deaths were documented (cancer deaths = 513 and CVD
deaths = 264). In both the age- and sex-adjusted models
and the multivariate models, baseline any vitamin/mineral
supplementation was not statistically significantly associ-
ated with cancer mortality or CVD mortality (Table 2).
The association for all-cause mortality was significantly
inverse in the age- and sex-adjusted model but attenuated
to a non-significant level in the multivariate model.
Excluding the deaths that occurred in the first 2 years of
follow-up did not substantially change the results, and none
of the null associations was modified by sex and smoking
status (data not shown).
In multivariate models, multivitamin supplementation
was not statistically significantly associated with any of the
end points. Antioxidant vitamin supplementation was sig-
nificantly inversely associated with cancer mortality (HR:
0.52; 95% CI: 0.28, 0.97) and all-cause mortality (HR:
0.58; 95% CI: 0.38, 0.88), but not with CVD mortality
(Table 3).
In the sub-analysis, new users, i.e. baseline non-users
who started taking supplements during follow-up, had a
significantly increased risk of cancer mortality (HR: 1.74;
95% CI: 1.09, 2.77) and all-cause mortality (HR: 1.58;
95% CI: 1.17, 2.14; Table 4). After new users were further
separated into new users of antioxidant vitamin supple-
ments (n = 445) and new users of other supplements
(n = 3,801), a HR for all-cause mortality of 1.23 (95% CI:
Table 2 Association of baseline any vitamin/mineral supplementation with cancer, cardiovascular, and all-cause mortality, the EPIC-Heidelberg
cohort, 1994–2010
No. of deaths HR (95% CI)
Sex- and age-adjusted model Multivariate modela
Cancer mortality
Non-users 353 1.00 1.00
Users 160 0.85 (0.70, 1.03) 0.88 (0.73, 1.07)
CVD mortality
Non-users 183 1.00 1.00
Users 81 0.84 (0.64, 1.10) 0.92 (0.70, 1.21)
All-cause mortality
Non-users 763 1.00 1.00
Users 338 0.86 (0.75, 0.98) 0.91 (0.80, 1.04)
Participants with a diagnosis of cancer or MI/stroke at baseline were excluded
BMI body mass index, CI confidence interval, CVD cardiovascular disease, EPIC European Prospective Investigation into Cancer and Nutrition,
HR hazard ratio, MI myocardial infarction, and NSAIDs non-steroidal anti-inflammatory drugs
a Adjusted for sex, age at recruitment, educational level, physical activity, BMI, waist-to-hip ratio, smoking category, intake of meat/meat
products, total energy intake, and baseline regular use of NSAIDs
Table 3 Association of baseline specific vitamin/mineral supplementation with cancer, cardiovascular, and all-cause mortality, the EPIC-
Heidelberg cohort, 1994–2010
No. of participants Cancer mortality CVD mortality All-cause mortality
No. of
deaths
HR
(95% CI)a
No. of
deaths
HR
(95% CI)a
No. of
deaths
HR
(95% CI)a
Non-use 15,811 353 1.00 183 1.00 763 1.00
Multivitamins 1,327 30 1.02 (0.70, 1.50) 9 0.71 (0.36, 1.39) 49 0.85 (0.63, 1.14)
Antioxidant vitaminsb 841 10 0.52 (0.28, 0.97) 8 0.74 (0.35, 1.58) 24 0.58 (0.38, 0.88)
Other supplements 5,964 120 0.90 (0.73, 1.12) 64 1.00 (0.75, 1.34) 265 0.97 (0.84, 1.11)
Participants with a diagnosis of cancer or MI/stroke at baseline were excluded
BMI body mass index, CI confidence interval, CVD cardiovascular disease, EPIC European Prospective Investigation into Cancer and Nutrition,
HR hazard ratio, MI myocardial infarction, and NSAIDs non-steroidal anti-inflammatory drugs
a Adjusted for sex, age at recruitment, educational level, physical activity, BMI, waist-to-hip ratio, smoking category, intake of meat/meat
products, total energy intake, and baseline regular use of NSAIDs
b Included vitamin A, C, E, and their combinations
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0.57, 2.66) was observed for the former and 1.63 (95% CI:
1.20, 2.21) for the latter. No statistically significant asso-
ciation was observed for cause-specific and all-cause
mortality among former users and consistent users,
although consistent users had a 50% lower risk of CVD
mortality (95% CI: 0.22, 1.17). Among casual users, there
was a positive yet not statistically significant association
for cancer mortality and all-cause mortality.
Discussion
After an 11-year follow-up of the EPIC-Heidelberg
cohort, regularly taking any vitamin/mineral supplements
was not statistically significantly associated with cancer,
CVD, or all-cause mortality. However, antioxidant vita-
min supplementation was significantly inversely associ-
ated with cancer mortality and all-cause mortality. In
comparison with never users, baseline non-users who
started taking vitamin/mineral supplements during follow-
up had significantly increased risks of cancer mortality
and all-cause mortality.
Cancer mortality
The null association we observed between baseline any
vitamin/mineral supplementation and cancer mortality
supports the finding of a prior prospective cohort study of
Swedish men, in which the investigated supplements were
also non-specific [6]. However, we did not see a signifi-
cantly increased risk of cancer mortality among any vita-
min/mineral supplement users who were current smokers
as observed in the Swedish male cohort [6]. The null
association between multivitamin supplementation and
cancer mortality in our cohort is in line with the findings of
a cohort study and a randomized clinical trial [2, 11], but
not consistent with the statistically significant positive
association observed among men of CPS-II [4].
The potential anticancer property of antioxidant vitamins
has been suggested by observational studies showing a
reduced risk of cancer mortality due to high intakes of fruits
and vegetables [12–15], which are abundant in antioxidant
vitamins. However, whether antioxidant vitamins from
supplements have a similar effect remains undetermined.
Two meta-analyses of randomized clinical trials suggest no
preventive effect of antioxidant vitamin supplements on
cancer incidence or mortality [16, 17], which is not sup-
ported by the finding of the present study. In the present
study, however, the small number of users of antioxidant
vitamin supplements and lack of detailed information on
dose, contents, and duration of use may weaken the con-
vincingness of the observed beneficial effect.
Several studies have suggested a possible reverse cau-
sality between vitamin/mineral supplementation and cancer
mortality by showing that cancer patients tend to take
vitamin/mineral supplements after the diagnosis [18–20].
In addition, certain health problems before cancer diag-
nosis are also possible to lead to use of vitamin/mineral
supplements, although this assumption has not been sug-
gested by literatures. The significantly increased risk of
cancer mortality we observed among new users was likely
to be caused by such a reverse causality. As an attempt to
remove this reverse causality, we excluded incident cancer
cases that were diagnosed between the baseline and the
date of the 3rd follow-up survey, and the association was
attenuated to a non-significant level (HR: 1.60; 95% CI:
0.87, 2.94).
Table 4 Association of any vitamin/mineral supplementation at baseline and during follow-up with cancer, cardiovascular, and all-cause
morality, the EPIC-Heidelberg cohort, 2004–2010
No. of participantsa Cancer mortality CVD mortality All-cause mortality
No. of
deaths
HR
(95% CI)b
No. of
deaths
HR
(95% CI)b
No. of
deaths
HR
(95% CI)b
Never users 7,540 39 1.00 31 1.00 101 1.00
New users 4,246 36 1.74 (1.09, 2.77) 18 1.06 (0.58, 1.94) 82 1.58 (1.17, 2.14)
Former users 2,229 11 1.01 (0.52, 2.00) 11 1.18 (0.57, 2.43) 32 1.14 (0.76, 1.71)
Casual users 2,299 19 1.72 (0.98, 3.00) 10 1.31 (0.63, 2.71) 37 1.38 (0.94, 2.04)
Consistent users 3,559 22 1.29 (0.75, 2.22) 7 0.50 (0.22, 1.17) 38 0.89 (0.61, 1.31)
BMI body mass index, CI confidence interval, CVD cardiovascular disease, EPIC European Prospective Investigation into Cancer and Nutrition,
HR hazard ratio, and NSAIDs non-steroidal anti-inflammatory drugs
a Only included participants who provided vitamin/mineral supplementation information at all three time points, i.e. the baseline face-to-face
interview, the 2nd and the 3rd follow-up survey. Participants with a diagnosis of cancer or MI/stroke at baseline were excluded
b Adjusted for sex, age at recruitment, educational level, physical activity, BMI, waist-to-hip ratio, smoking category, intake of meat/meat
products, total energy intake, and baseline regular use of NSAIDs
Eur J Nutr (2012) 51:407–413 411
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CVD mortality
The present study and the Swedish male cohort study [6]
are in agreement on the null association between use of any
vitamin/mineral supplements and CVD mortality. As for
the association between multivitamin supplementation and
CVD mortality, previous findings are conflicting. In a large
cohort study, the Physicians’ Health Study, multivitamin
supplementation was not statistically associated with CVD
mortality [3]. In another cohort study, however, the asso-
ciation between multivitamin supplementation in a fre-
quency of 6–7 days/week and CVD mortality was
significant and inverse [6]. For antioxidant vitamin sup-
plements, two clinical trials provided no evidence of
association with CVD mortality [21, 22], although CPS-II
observed an inverse association for ischaemic heart disease
mortality [4].
In the sub-analysis, the statistically non-significant
inverse association for CVD mortality among consistent
users was based on an average follow-up time of 3.0 years
and only seven CVD deaths. A future analysis based on a
prolonged follow-up time and more CVD deaths might
produce more convincing results.
All-cause mortality
Our finding of an inverse although statistically non-sig-
nificant association between any vitamin/mineral supple-
mentation and all-cause mortality does not fully support
the null association observed in the Swedish male cohort
(HR: 1.00; 95% CI: 0.90–1.11) [6]. Our finding also does
not support the significant positive association between
regular multivitamin supplementation and all-cause mor-
tality in CPS-II [4]. However, that positive association
observed in CPS-II is likely to be spurious because the
study did not exclude baseline pre-existing CVD and
cancer cases.
The significant inverse association between antioxidant
vitamin supplementation and all-cause mortality in the
EPIC-Heidelberg cohort is consistent with the finding of
CPS-II [4]. However, two randomized clinical trials sug-
gest that supplementation of beta-carotene or vitamin E in
high dose may increase the risk of all-cause mortality in
smokers [21, 23]. In the present study, we could not
investigate such an adverse effect because of the fewness
of antioxidant vitamin supplement users among current
smokers (n = 171).
In the sub-analysis, the significantly increased risk of
all-cause morality among new users of any vitamin/mineral
supplements may suggest a ‘‘sick-user effect,’’ implying
that initiation of supplementation during follow-up could
be caused by the occurrence of certain health problems.
The disparity in the strength of this positive association
between new users of antioxidant vitamin supplements and
new users of other supplements was possibly due to the
potential beneficial effect of antioxidant vitamin supple-
ments on all-cause mortality as suggested by the present
study.
In observational studies, the validity of self-reported
vitamin/mineral supplementation is difficult to measure,
although some researchers used 24-h recall interviews or
label transcriptions to identify ‘‘real users’’ [24, 25].
However, different definitions (regular use over weeks or
months versus 24-h usage of supplements) make compar-
isons difficult. In the present study, we could compare two
separate assessments at baseline, and the reliability of these
self-reported vitamin/mineral supplementation data was
high, as suggested by the weighted Kappa coefficient of
0.87. In the present study, we were unable to investigate
the dose–response relationship because dose data were not
available. Although 43.7% of supplement users did not
provide the brand names of the supplements they took, it is
unlikely that this causes substantial bias.
As vitamin/mineral supplementation is a changeable
behavior among free-living individuals, prospective studies
that only perform one single assessment at baseline may
suffer from exposure misclassification. The present study
assessed vitamin/mineral supplementation not only at
baseline but also during follow-up; we thus were allowed
to handle this changeable behavior by categorizing par-
ticipants into various patterns according to their supple-
mentation status at sequential time points. Nevertheless, it
needs to be noted that, because the survival time in our sub-
analysis was counted from the date of the last assessment,
i.e., the 3rd follow-up survey, the average follow-up time
of the sub-cohort was only 3.0 years, which is obviously
not long enough to evaluate the exposure-disease associa-
tions for cancer and CVD.
In conclusion, this study provides no evidence that any
vitamin/mineral or multivitamin supplementation may
reduce the risks of cancer, CVD, or all-cause mortality.
Based on limited numbers of users and cases, this study
suggests that supplementation of antioxidant vitamins
might possibly reduce cancer and all-cause mortality. The
significantly increased risks of cancer and all-cause mor-
tality among baseline non-users who started taking sup-
plements during follow-up may suggest a ‘‘sick-user
effect,’’ which researchers should be cautious of in future
observational studies.
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